M Kaufmann1, S Hartl, K Geyer, M K Breyer, O C Burghuber. 1. Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD, Otto Wagner Hospital, Vienna, Austria. monika.kaufmann@wienkav.at
Abstract
BACKGROUND: The prevalence of asthma and chronic obstructive pulmonary disease (COPD) is high ( approximately 7.4-18%) in the general population, but less than half are diagnosed. Several studies have shown FEV(6) as a good surrogate marker for forced vital capacity (FVC) to detect airflow limitations. OBJECTIVES: The aim of this study was to evaluate if it is possible to simplify and improve the diagnosis of so far undiagnosed asthma or COPD in the primary care setting by measuring FEV(6) with a new simple screening device (PiKo-6). METHODS: 507 patients were recruited from three general practices from May to June 2005. Patients with any known pulmonary disease were excluded by questionnaire. FEV(1), FEV(6) and FEV(1)/FEV(6) were determined using a PiKo-6 device. Patients with an FEV(1)/FEV(6) <80% (PiKo positive) were invited to a standardized pulmonary function test to confirm or rule out airflow limitation. RESULTS: 401 (79.1%) patients showed FEV(1)/FEV(6) > or =80% (PiKo negative), and 106 (20.9%) patients were PiKo positive. Of the 106 PiKo-positive patients, 74 patients (14.7% of total) agreed to further studies and 18 patients (3.6%) of them suffered from COPD [COPD 0: 5 (1.0%); COPD I: 9 (1.8%); COPD II: 4 (0.8%), and none with COPD III or IV] and 14 patients (2.8%) suffered from bronchial hyperresponsiveness or asthma. In 42 patients (8.3%), the pulmonary function test was normal. CONCLUSIONS: Measurement of FEV(6) using a new simple screening device (PiKo-6) may improve the detection rate of undiagnosed airflow limitation in the primary care setting. However, patients should be carefully selected.
BACKGROUND: The prevalence of asthma and chronic obstructive pulmonary disease (COPD) is high ( approximately 7.4-18%) in the general population, but less than half are diagnosed. Several studies have shown FEV(6) as a good surrogate marker for forced vital capacity (FVC) to detect airflow limitations. OBJECTIVES: The aim of this study was to evaluate if it is possible to simplify and improve the diagnosis of so far undiagnosed asthma or COPD in the primary care setting by measuring FEV(6) with a new simple screening device (PiKo-6). METHODS: 507 patients were recruited from three general practices from May to June 2005. Patients with any known pulmonary disease were excluded by questionnaire. FEV(1), FEV(6) and FEV(1)/FEV(6) were determined using a PiKo-6 device. Patients with an FEV(1)/FEV(6) <80% (PiKo positive) were invited to a standardized pulmonary function test to confirm or rule out airflow limitation. RESULTS: 401 (79.1%) patients showed FEV(1)/FEV(6) > or =80% (PiKo negative), and 106 (20.9%) patients were PiKo positive. Of the 106 PiKo-positive patients, 74 patients (14.7% of total) agreed to further studies and 18 patients (3.6%) of them suffered from COPD [COPD 0: 5 (1.0%); COPD I: 9 (1.8%); COPD II: 4 (0.8%), and none with COPD III or IV] and 14 patients (2.8%) suffered from bronchial hyperresponsiveness or asthma. In 42 patients (8.3%), the pulmonary function test was normal. CONCLUSIONS: Measurement of FEV(6) using a new simple screening device (PiKo-6) may improve the detection rate of undiagnosed airflow limitation in the primary care setting. However, patients should be carefully selected.
Authors: Lisette van den Bemt; Bram C W Wouters; Joke Grootens; Joke Denis; Patrick J Poels; Tjard R Schermer Journal: NPJ Prim Care Respir Med Date: 2014-08-14 Impact factor: 2.871
Authors: Francisco Franco-Marina; Rosario Fernandez-Plata; Luis Torre-Bouscoulet; Cecilia García-Sancho; Elisa Sanchez-Gallen; David Martinez; Rogelio Perez-Padilla Journal: NPJ Prim Care Respir Med Date: 2014-05-20 Impact factor: 2.871
Authors: Cristina Represas-Represas; Alberto Fernández-Villar; Alberto Ruano-Raviña; Ana Priegue-Carrera; Maribel Botana-Rial Journal: PLoS One Date: 2016-01-04 Impact factor: 3.240
Authors: Rogelio Perez-Padilla; Fernando C Wehrmeister; Bartolome R Celli; Maria Victorina Lopez-Varela; Maria Montes de Oca; Adriana Muiño; Carlos Talamo; Jose R Jardim; Gonzalo Valdivia; Carmen Lisboa; Ana Maria B Menezes Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240
Authors: A P Dickens; D A Fitzmaurice; P Adab; A Sitch; R D Riley; A Enocson; R E Jordan Journal: NPJ Prim Care Respir Med Date: 2020-01-03 Impact factor: 2.871